作　　者： (）;

机构地区： 南方医科大学

出　　处： 《中国现代药物应用》 2018年第23期78-79,共2页

摘　　要： 目的分析司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床效果。方法 86例帕金森病运动障碍患者,应用黑白双色球抽签方法分为对照组与研究组,每组43例。对照组患者使用左旋多巴治疗,研究组患者在对照组基础上使用司来吉兰治疗。对比两组患者的临床疗效及治疗前后帕金森氏病综合评分量表(UPDRS)评分。结果研究组患者的治疗总有效率为97.67%,显著高于对照组的76.74%,差异具有统计学意义(P<0.05)。治疗前两组UPDRS评分比较差异无统计学意义(P>0.05);治疗2、4周后,研究组UPDRS评分分别为(30.12±1.43)、(28.14±1.29)分,均低于对照组的(34.98±1.57)、(33.67±1.52)分,差异具有统计学意义(P<0.05)。结论对于帕金森病运动障碍患者而言,应用司来吉兰联合左旋多巴治疗效果显著,可有效改善患者运动障碍程度,且治疗安全性较高,值得推广。 Objective To analyze the clinical effect of selegiline combined with levodopa in the treatment of Parkinson’s disease dyskinesia.Methods A total of 86 patients with Parkinson’s disease dyskinesia were divided by black and white ball drawing method into control group and research group,with 43 cases in each group.The control group was treated with levodopa,and the research group was treated with selegiline on the basis of the control group.The clinical efficacy and unified Parkinson’s disease rating scale(UPDRS)score before and after treatment between the two groups was compared.Results The research group had significantly higher total treatment effective rate as 97.67%than 76.74%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in UPDRS score(P>0.05).After 2 and 4 weeks of treatment,the research group had lower UPDRS score respectively as(30.12±1.43)and(28.14±1.29)points than(34.98±1.57)and(33.67±1.52)points in the control group,and their difference was statistically significant(P<0.05).Conclusion Application of selegiline and levodopa shows remarkable effect in treating patients with Parkinson’s disease dyskinesia,and it can effectively improve the degree of dyskinesia in patients with high safety.So it is worth promoting.

关 键 词： 司来吉兰 左旋多巴 帕金森病 运动障碍

领　　域： []